Postmarket Surveillance Is Sound Investment For Industry – Niedelman
This article was originally published in The Gray Sheet
Executive Summary"The Gray Sheet" recently spoke with former FDA Deputy Associate Commissioner for Regulatory Operations, Steven Niedelman, who left the agency at the end of June to become executive vice president of Quintiles Transnational Corp. He will head the company's Quintiles Consulting group
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.